Abstract
Objective
To investigate whether lateral lymph node (LLN) dissection (LLND) can be exempted in patients with good tumor regression grading (TRG) after neoadjuvant chemoradiotherapy (nCRT)?
Methods
A retrospective study was conducted on consecutive patients with advanced rectal cancer who underwent nCRT and total mesorectal resection plus selective LLND at our institution. The primary outcomes are the relationship between LLN metastasis (LLNM) and magnetic resonance imaging TRG (mrTRG) and the relationship between LLNM and pathological TRG (pTRG).
Results
A total of 91 patients were included, of which 24 patients (26.4%) had LLNM, 67 patients (73.6%) had no LLNM. There were significant differences of the maximum short-axis of LLN before and after nCRT, short-axis reduction rate of the LLN with maximum short-axis, length diameter reduction rate of primary tumor, mrTRG, and pTRG between the two groups. Multivariate logistic regression showed that mrTRG (P = 0.026) and pTRG (P = 0.013) were independent predictors for LLNM. The combination used by mrTRG and the maximum short-axis of LLNs ≥ 8 mm before nCRT and the maximum short-axis of LLN ≥ 5 mm after nCRT achieved specificity of 0.970, positive predictive value (PPV) of 0.867, and negative predictive value (NPV) of 0.855. The same combination used by pTRG achieved the specificity of 0.970, PPV of 0.857 and NPV of 0.844.
Conclusion
The suspected positive LLNs tend to be sterilized by nCRT in patients who have a very good response to nCRT. It is rational to avoid LLND in patients whose primary tumor and LLNs both show good response to nCRT.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
The treatment of advanced rectal cancer patients with suspected positive lateral lymph node (LLN) remains controversial between Eastern and Western scholars [1, 2]. In West, neoadjuvant chemoradiotherapy (nCRT) combined with total mesorectal excision (TME) is the standard treatment [3]. However, the standard treatment method in East represented by Japan is TME with prophylactic lateral lymph node (LN) dissection (pLLND) [4]. In China, based on the results of Akiyoshi et al. [5], selective lateral lymph node dissection (sLLND) is recommended if suspected positive LLN is detected on pre-treatment imaging, and pLLND is not performed if there is no suspected positive LLN [6].
Recently, there were some studies [7, 8] reported that TME with sLLND after nCRT was more beneficial to reduce lateral local recurrence (LLR) and improve overall survival (OS) for advanced rectal cancer patients with suspected lateral lymph node metastasis (LLNM). Therefore, both Western and Eastern scholars have gradually become interested in TME plus sLLND after nCRT for such diseases [9]. However, there is no consensus on what kinds of patients should undergo sLLND after nCRT and what kinds should be exempted. Therefore, the clinical management of such patients requires more rigorous and optimal evaluation.
In previous reports, pathological tumor regression grading (pTRG) have been established as an important factor for the survival outcomes of patients with advanced rectal cancer after nCRT and also confirmed to be closely associated with mesorectal LN (MLN) regression grading (LRG) [10,11,12,13]. TRG and LRG showed the same trend in esophageal [14] and breast [15] cancer as well as rectal cancer. Moreover, a new magnetic resonance imaging (MRI) TRG (mrTRG) scheme for advanced rectal cancer was developed by Peng et al. [16], which had good agreement with pTRG classification scheme. Therefore, we hypothesized that the regression of LLN was also correlated with pTRG and mrTRG in advanced rectal cancer patients after nCRT, which was worthy of further investigation.
We designed this retrospective study to evaluate the relationship between LLNM and pTRG and mrTRG in advanced rectal cancer patients with suspected LLNM after nCRT. It aimed to guide decision-making of clinical sLLND and the further treatment of patients with suspected LLNM but without LLND.
2 Materials and methods
2.1 Study population
This single-center cohort study was ethically approved by our institutional ethics committee and exempted from informed consent since it was retrospective.
Consecutive patients with advanced rectal cancer and suspected LLNM in our hospital who underwent TME plus sLLND after nCRT between December 2014 and June 2022 were retrospectively collected, and the data were extracted from a prospectively maintained database. The eligible criteria were as follows: rectal adenocarcinoma patients with suspected LLNM who underwent TME plus sLLND after nCRT. Patients with the following conditions were excluded: (1) multiple primary cancers; (2) recurrent rectal cancer; (3) previously treated for other cancers; (4) incomplete clinical data; (5) Stage IV patients. Pathological outcomes were used as the gold standard.
Node-to-node correspondence between preoperative and postoperative LLN on MRI image and pathology was achieved according to an ongoing clinical trial (U.S. clinical trial registration platform registration: NCT03826862). The specific experimental method was also described in our previous literature [17] (Figure S1).
2.2 Treatment
The pretreatment clinical staging was mainly based on physical examination, laboratory examination, rectal ultrasound, computed tomography (CT) scan and MRI. T staging and N staging were divided according to the American Joint Committee on Cancer (AJCC) 8th staging system. The criteria of nCRT for patients with advanced rectal cancer referred to Chinese expert consensus on the diagnosis and treatment for lateral lymph node metastasis of rectal cancer [6]. The nCRT regimen was long-course CRT (45–50.4 Gy) based on 5-FU, or short-course CRT (25 Gy), and the radiotherapy area covered the lateral area. Surgery was performed 6–8 weeks after nCRT. The classification of LLN tiers referred to the Japanese guidelines [1]. Standard TME with sLLND would be performed as long as the suspected positive LLN before nCRT was still visible on imaging after nCRT (no matter how small the regression was) (Fig. 1) [18, 19]. The extent of LLND: LNs in internal iliac (263d, 263p) and obturator (283) areas were routinely dissected, while LNs in external iliac or common iliac areas was dissected only when there was suspected positive LN in these two areas. Bilateral LLND should only be considered when there were suspected positive LLN in both pelvic sidewalls. Postoperative adjuvant chemotherapy was only given to the patients with high risk factors according to pathological outcomes.
2.3 MRI assessment
Mesoretal fascia (MRF), extramural venous invasion (EMVI), mrTRG and tumor length diameter were assessed by an associate chief (T.Z.) of radiology with 15 years of experience pelvic MRI. MRF [20] and EMVI [21] were evaluated according to previous studies (Table S1 and Table S2). The four-category mrTRG system was defined as follows [16] : mrTRG 0, where there was no remaining tumor tissue; mrTRG 1, where no more than 30% of the tumor remained; mrTRG 2, where 30 to 80% of the tumor remained and mrTRG 3, where more than 80% of the tumor remained. mrTRG 0–1 was regarded as good regression, and mrTRG 2–3 as poor regression. The length diameter reduction rate of tumor was defined as (Lpre–Lpost/Lpre) × 100%, where Lpre and Lpost are the maximum length diameter of tumor before and after nCRT, respectively (Fig. 2).
Referring to previous literature [22], MRI-positive criteria for LLN before nCRT were according to the maximum short-axis and malignant features (round, irregular borders and heterogeneity) in the MRI imaging before nCRT. The MRI-positive criteria for LLN after nCRT were according to the maximum short-axis in the MRI imaging after nCRT (Table S3). The short-axis reduction rate of LLN was defined as (Spre–Spost / Spre) × 100%, where Spre and Spost are the maximum short-axis of the LLN before and after nCRT, respectively. According to the previous literature [8, 22,23,24], this study selected the largest LLN as the target lymph node.
2.4 Pathological assessment
Pathological outcomes of LLN and pTRG were judged by a deputy chief physician (D.J.) of the pathology department with more than 10 years of working experience. The four-category AJCC/CAP pTRG system was classified as follows [25, 26]: TRG 0, no residual tumor cells; TRG 1, single cells or small groups of cells; TRG 2, residual cancer with a desmoplastic response; TRG 3, no significant tumor regression. TRG 0–1 was regarded as good regression, and TRG 2–3 as poor regression [10].
2.5 Statistical analysis
Categorical data were presented as number and percentage and were compared by Pearson's chi-square test or Fisher's exact test. When continuous variables conform to normal distribution, they were expressed as mean ± standard deviation and compared by t test; continuous variables were expressed as median sum (min–max) when non-normal distribution is used, and Wilcoxon test was used for comparison. Cohen kappa test was used to check the consistency between mrTRG and pTRG [27]. The kappa values just like as Landis and Koch classification [28] (0.00, poor agreement; 0.00–0.20, slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement, and 0.81–1.00, excellent agreement). All available variables were used as independent variables, and logistic regression analysis was used to evaluate the relationships with LLNM. All data were analyzed by SPSS 23 Statistics software (version 23; IBM, Armonk, NY), and P < 0.05 was determined to be statistically significant. The graph was produced by the software GraphPad Prism 8.0.1.
3 Results
3.1 Patient characteristics
There were 122 advanced rectal cancer patients with suspected positive LLN who received TME with sLLND after nCRT were included. Among them, two patients were excluded due to multiple primary cancers; two patients were excluded due to recurrent rectal cancer; three patients were excluded due to previously treated for other cancer; six patients were excluded due to incomplete clinical data; seven patients were exclude due to Stage IV; 11 patients with short-term radiotherapy were excluded due to none of them had MRI after treatment (Fig. 3).
Finally, 91 patients were included in this study, of which 24 patients (26.4%) had LLNM, 67 patients (73.6%) had no LLNM. The regional distribution of the LLN with the maximum short-axis was three in external iliac area, 40 in obturator area, and 48 in internal iliac area. Thirty-three patients were classified as mrTRG 0–1 (eight as mrTRG 0, 25 as mrTRG 1), while 58 patients were classified as mrTRG 2–3 (37 as mrTRG 2, 21 as mrTRG 3). Forty-one patients were classified as pTRG 0–1 (22 as pTRG 0, 19 as pTRG 1), while 50 patients were classified as pTRG 2–3 (42 as pTRG 2, eight as pTRG 3).The consistence between mrTRG and pTRG checked by Cohen kappa test was acceptable (к = 0.684).
The details of clinical characteristics, imaging data and pTRG were respected in Tables 1 and 2. There were no statistically differences of sex, age, distance from anal verge, pre-nCRT carcinoembryonic antigen (CEA), post-nCRT CEA, location of the LLN with the maximum short-axis, clinical T stage, clinical N stage, AJCC stage, pre-nCRT MRF, pre-NCRT EMVI, and pre-nCRT LLN status between the patients with LLNM and those without LLNM (P > 0.05) (Tables 1 and 2). There were statistically significant differences of the maximum short-axis of LLN before nCRT (P = 0.016), whether the maximum short-axis of LLN ≥ 8 mm before nCRT (P = 0.001), the maximum short-axis of LLN after nCRT (P < 0.001), whether the maximum short-axis of LLN ≥ 5 mm after nCRT (P < 0.001), short-axis reduction rate of the LLN with maximum short-axis (P = 0.001), length diameter reduction rate of primary tumor (P = 0.044), mrTRG (P = 0.004), and pTRG (P < 0.001) between the two groups (Table 2).
3.2 LLNM and mrTRG
The incidence of LLNM was significantly higher in patients with mrTRG 2–3 than in patients with mrTRG 0–1 (P = 0.004) (Table 2). Univariate analysis showed pre-nCRT CEA (P = 0.074), the maximum short axis of LLN before nCRT (P = 0.026), whether the maximum short axis of LLN ≥ 8 mm before nCRT (P = 0.001), the maximum short axis of LLN after nCRT (P = 0.002), whether the maximum short axis of LLN ≥ 5 mm after nCRT (P < 0.001), short axis reduction rate of the LLN with maximum short-axis (P < 0.001), length diameter reduction rate of primary tumor (P = 0.048), mrTRG (P = 0.009) and pTRG (P = 0.001)were potential risk factors for LLNM (Table 3). Multivariate analysis (excluded pTRG since they were corrected, к = 0.684) showed only mrTRG (OR = 0.12, 95% CI: 0.02–0.78, P = 0.026) was an independent predictor for LLNM (Table 3). Only using mrTRG to predict LLNM achieved the sensitivity of 0.875, specificity of 0.448, positive predictive value (PPV) of 0.362, and negative predictive value (NPV) of 0.909 (Table 4). mrTRG, the maximum short-axis of LLNs ≥ 8 mm before nCRT, the maximum short-axis of LLN ≥ 5 mm after nCRT, were combined to predict LLNM. Risk score A was defined as follows: Score 1: mrTRG 2–3 AND the maximum short-axis of LLNs ≥ 8 mm before nCRT AND the maximum short-axis of LLN ≥ 5 mm after nCRT; Score 0: The rest situations. Risk score A achieved the sensitivity of 0.542, specificity of 0.970, PPV of 0.867, and NPV of 0.855 (Table 4).
3.3 LLNM and pTRG
The incidence of LLNM in patients with pTRG 2–3 was also significantly higher than in patients with pTRG 0–1 (P < 0.001) (Table 2). Univariate analyses for potential risk factors of LLNM were showed above. Multivariate analysis (excluded mrTRG since they were corrected, к = 0.684) showed only pTRG (OR = 0.11, 95% CI: 0.03–0.40, P = 0.001) was an independent predictor for LLNM (Table 3). Only using pTRG to predict LLNM achieved the sensitivity of 0.875, specificity of 0.567, PPV of 0.420 and NPV of 0.927 (Table 4). pTRG, the maximum short-axis of LLNs ≥ 8 mm before nCRT, the maximum short-axis of LLN ≥ 5 mm after nCRT, were combined to predict LLNM. Risk score B was defined as follows: Score 1: pTRG 2–3 AND the maximum short-axis of LLNs ≥ 8 mm before nCRT AND the maximum short-axis of LLN ≥ 5 mm after nCRT; Score 0: The rest situations. Risk score B achieved the sensitivity of 0.500, specificity of 0.970, PPV of 0.857 and NPV of 0.844 (Table 4).
3.4 Subgroup analysis
When grouped by mrTRG, it was found that there was no difference in the maximum short-axis of LLN before and after nCRT and the short-axis reduction rate. However, when grouped by pTRG, the short-axis reduction rate in pTRG 0–1 was significantly higher than that in pTRG 2–3(P = 0.049) (Table 5). The scatter diagram of the short-axis reduction rate was shown in Fig. 4.
4 Discussion
Previous studies suggested that the probability of LLNM in advanced rectal cancer was 10%-25% [29, 30]. LLNM also is an independent risk factor for poor prognosis in advanced rectal cancer [31]. Therefore, LLN should not be ignored in the treatment of advanced rectal cancer. The incidence of LLNM in patients with suspected positive LLN before operation was 8.1%-51.6% after nCRT [8, 24, 32]. The incidence in this study was 26.4%. It demonstrated that nCRT with TME alone was not enough to ensure the R0 resection of such patients. Meanwhile enlarged LLN is a high risk factor for LLR [33, 34]. Therefore, TME plus sLLND after nCRT for such diseases is necessary. However, which patients should be performed LLND is always discussed, but which patients should be exempted from LLND is rarely mentioned in clinic.
Previous studies suggested the maximum short-axis was closely related to LLNM [8, 23, 24], and chose 8 mm before nCRT [23, 24] and 5 mm after nCRT [8, 22] as the cut-off values. The cut-off values in this study also obtained the similar results, whether it was the maximum short-axis before and after nCRT or the cut-off values of the maximum short-axis before and after nCRT, there were significant differences between the two groups.
At present, increasing numbers of studies suggested that the comprehensive treatment strategy of combined nCRT and sLLND is for advanced rectal cancer patients with suspected LLNM based on imaging findings [7, 8, 35]. Accurate assessment and application of TRG was not only of great significance for predicting the prognosis of patients with advanced rectal cancer, but also for guiding the "watch and wait" strategy [36]. In previous reports, mrTRG system developed by MERCURY study identified a favorable outcome subgroup with extended OS and disease-free survival rate (DFS) [37, 38]. It was similar to pTRG principle, however, whether that mrTRG system could be used as a substitute for pTRG system remains controversial due to the poor consistency with pTRG [39,40,41].
Fortunately, a new four-category mrTRG system developed by Pang et al.[16] achieved good agreement with pTRG (к = 0.671) while achieving good efficiency in identifying complete pathological responses. Therefore, we chose this system to evaluate the mrTRG of our patients. According to our results, the consistence between mrTRG and pTRG was good agreement (к = 0.684). It demonstrated that the understanding of this mrTRG system was correct and the results were reliable. Multivariate logistic regression showed that mrTRG and pTRG were the independent predictors of LLNM, respectively. Sun et al. [10] found that mesorectal LRG was basically consistent with pTRG. Although we did not assess lateral LRG, our results showed that the LLNM and TRG also remained highly consistent no matter which system of TRG was chosen. Only using mrTRG to predict LLNM achieved the sensitivity of 0.875 and NPV of 0.909. Only using pTRG to predict LLNM achieved the basically same results (sensitivity of 0.875, NPV of 0.927). The results of subgroup analysis also showed that the short-axis reduction rate in pTRG 0–1 was significantly higher than that in pTRG 2–3. It illustrated that the sensitivity of LLN to nCRT was identical to primary tumor. In addition, under the condition of good agreement between mrTRG and pTRG, different results were found when mrTRG and pTRG were used to analyze the short-axis reduction rate, which may be related to the small number of cases in this study, and small data changes could affect the final results. The length diameter reduction rate of primary tumor is related to TRG, so there are differences between groups and in univariate analysis, but it is meaningless in multivariate analysis. I wonder if this is related to our small sample size.
The combination of mrTRG, the maximum short-axis of LLNs ≥ 8 mm before nCRT and the maximum short-axis of LLN ≥ 5 mm after nCRT was named to Risk score A, which achieved satisfactory specificity (0.970), acceptable PPV (0.867) and NPV (0.855). The same combination used by pTRG was named Risk score B, which also achieved the satisfactory specificity (0.970), acceptable PPV (0.857) and NPV (0.844). These two risk scores show their good sensitivity to true negative LLN, which had important guiding significance for sLLND. Although it could not help us accurately determine which patient should undergo sLLND, it told us when physical examination, laboratory tests and imaging examinations indicated that the primary tumor and the suspected positive LLN all obtained good regression after nCRT, we should be cautious in performing LLND. Therefore, accurate assessment of the regression of primary tumor and suspected positive LLN could avoid unnecessary LLND. At the same time, because the East and the West have not reached an agreement on the treatment strategy of patients with suspected LLNM, there must be many patients who are indicative of sLLND might not have received it. Our results also had positive guiding significance for further treatment of this part of patients. The accurate pTRG and the changes in the maximum short-axis of suspected positive LLN before and after nCRT could tell us which patient should be safe to choose "watch and wait".
Different to previous studies, our results revealed that the positive rate of LLNs was not related to the location [42]. The possible reason may be that we only analyzed the LLNs with maximum short-axis. Previous studies revealed that age, female, low rectal cancer, EMVI positive, MRF positive, CEA were not statistically significant related to LLNs status [43],which were similar to our results.
The shortcomings of this study were as follows: firstly, the number of cases was relatively small, which was not enough to establish a prediction model. Secondly, it was impossible to analyze the relationship between clinical complete regression and LLNM because the colonoscopy data before nCRT of many patients were unavailable. Thirdly, because most patients had a short follow-up period (less than 2 years), we lacked the analysis of long-term outcome for these patients. However, this result can be utilized to avoid an unnecessary LLND when the responses of primary tumor and LLNs to nCRT are both good.
5 Conclusion
The suspected positive LLNs tend to be sterilized by nCRT in patients who have a very good response to nCRT. This study suggests that it is rational to avoid LLND in patients whose primary tumor and LLNs both show good response to nCRT.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
Williamson JS, Quyn AJ, Sagar PM. Rectal cancer lateral pelvic sidewall lymph nodes: a review of controversies and management. Br J Surg. 2020;107(12):1562–9.
Ahmadi N, Brown KGM, Lee P, Quinn M, Austin KKS, Solomon MJ. Is neoadjuvant chemoradiotherapy sufficient in patients with advanced rectal malignancy and positive extra-mesorectal lateral lymph nodes? Colorectal Dis. 2020;22(6):689–93.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20(2):207–39.
Akiyoshi T, Ueno M, Matsueda K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Unno T, Kano A, Kuroyanagi H, et al. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol. 2014;21(1):189–96.
Chinese expert consensus on the diagnosis and treatment for lateral lymph node metastasis of rectal cancer (2019 edition). Zhonghua Wei Chang Wai Ke Za Zhi 2019, 22(10):901–912.
Kim MJ, Kim TH, Kim DY, Kim SY, Baek JY, Chang HJ, Park SC, Park JW, Oh JH. Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer? J Surg Oncol. 2015;111(4):459–64.
Malakorn S, Yang Y, Bednarski BK, Kaur H, You YN, Holliday EB, Dasari A, Skibber JM, Rodriguez-Bigas MA, Chang GJ. Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation? Dis Colon Rectum. 2019;62(10):1158–66.
Agger E, Åkerlund V, Ekberg O, Jörgren F, Lydrup ML, Buchwald P. Management, treatment and prognostic significance of lateral lymph node metastases in rectal cancer-a regional cohort study. Int J Colorectal Dis. 2021;36(12):2707–14.
Sun Y, Wu X, Lin H, Lu X, Huang Y, Chi P. Lymph node regression to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: prognostic implication and a predictive model. J Gastrointest Surg. 2021;25(4):1019–28.
Caricato M, Ausania F, De Dominicis E, Vincenzi B, Rabitti C, Tonini G, Cellini F, Coppola R. Tumor regression in mesorectal lymphnodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol. 2007;33(6):724–8.
Fernández-Aceñero MJ, Granja M, Sastre J, García-Paredes B, Estrada L. Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma. Virchows Arch. 2016;468(4):425–30.
Li J, Yuan J, Liu H, Yin J, Liu S, Du F, Hu J, Li C, Niu X, Lv B, et al. Lymph nodes regression grade is a predictive marker for rectal cancer after neoadjuvant therapy and radical surgery. Oncotarget. 2016;7(13):16975–84.
Philippron A, Bollschweiler E, Kunikata A, Plum P, Schmidt C, Favi F, Drebber U, Hölscher AH. Prognostic relevance of lymph node regression after neoadjuvant chemoradiation for esophageal cancer. Semin Thorac Cardiovasc Surg. 2016;28(2):549–58.
Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7.
Pang X, Xie P, Yu L, Chen H, Zheng J, Meng X, Wan X. A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer. Br J Cancer. 2022;127(2):268–77.
Liu X, Wei M, Zhu Y, Wang Z. Letter to the editor on “diagnosis and treatment of small rectal neuroendocrine tumors with simultaneous lateral lymph nodes metastasis.” Asian J Surg. 2022. https://doi.org/10.1016/j.asjsur.2022.03.104.
Ogawa S, Hida J, Ike H, Kinugasa T, Ota M, Shinto E, Itabashi M, Okamoto T, Sugihara K. The important risk factor for lateral pelvic lymph node metastasis of lower rectal cancer is node-positive status on magnetic resonance imaging: study of the lymph node committee of japanese society for cancer of the colon and rectum. Int J Colorectal Dis. 2016;31(10):1719–28.
Yang X, Jin C, Deng X, Wang M, Zhang Y, Wei M, Meng W, Wang Z. Laparoscopic extralevator abdominoperineal excision of the rectum with primary suturing: short-term outcomes from single-institution study. J Laparoendosc Adv Surg Tech A. 2016;26(1):40–6.
Vliegen RF, Beets GL, Lammering G, Dresen RC, Rutten HJ, Kessels AG, Oei TK, de Bruïne AP, van Engelshoven JM, Beets-Tan RG. Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology. 2008;246(2):454–62.
Chand M, Swift RI, Tekkis PP, Chau I, Brown G. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer. 2014;110(1):19–25.
Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol. 2004;52(1):78–83.
Yang X, Gu C, Hu T, Wei M, Meng W, Wang Z, Deng X, Zhou Z. Indications and oncological outcomes of selective dissection for clinically suspected lateral lymph node metastasis in patients with rectal cancer based on pretreatment imaging. Tech Coloproctol. 2021;25(4):425–37.
Kawai K, Shiratori H, Hata K, Nozawa H, Tanaka T, Nishikawa T, Murono K, Ishihara S. Optimal size criteria for lateral lymph node dissection after neoadjuvant chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2021;64(3):274–83.
Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O’Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.
Mace AG, Pai RK, Stocchi L, Kalady MF. American joint committee on cancer and college of american pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58(1):32–44.
Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101(10):639–41.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
Moriya Y. Treatment of lateral pelvic nodes metastases from rectal cancer: the future prospective. G Chir. 2013;34(9–10):245–8.
Kim DJ, Chung JJ, Yu JS, Cho ES, Kim JH. Evaluation of lateral pelvic nodes in patients with advanced rectal cancer. AJR Am J Roentgenol. 2014;202(6):1245–55.
Ueno M, Oya M, Azekura K, Yamaguchi T, Muto T. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg. 2005;92(6):756–63.
Ishihara S, Kawai K, Tanaka T, Kiyomatsu T, Hata K, Nozawa H, Morikawa T, Watanabe T. Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. Dis Colon Rectum. 2017;60(5):469–76.
Kim MJ, Chan Park S, Kim TH, Kim DY, Kim SY, Baek JY, Chang HJ, Park JW, Oh JH. Is lateral pelvic node dissection necessary after preoperative chemoradiotherapy for rectal cancer patients with initially suspected lateral pelvic node? Surgery. 2016;160(2):366–76.
Akiyoshi T, Matsueda K, Hiratsuka M, Unno T, Nagata J, Nagasaki T, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, et al. Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low-rectal cancer. Ann Surg Oncol. 2015;22(Suppl 3):S614-620.
Kim TH, Jeong SY, Choi DH, Kim DY, Jung KH, Moon SH, Chang HJ, Lim SB, Choi HS, Park JG. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008;15(3):729–37.
Germani P, Di Candido F, Léonard D, Cuicchi D, Elmore U, Allaix ME, Barbieri VP, D’Allens L, Faes S, Milani M, et al. Contemporary snapshot of tumor regression grade (TRG) distribution in locally advanced rectal cancer: a cross sectional multicentric experience. Updates Surg. 2021;73(5):1795–803.
Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753–60.
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016;27(8):1557–65.
van den Broek JJ, van der Wolf FS, Lahaye MJ, Heijnen LA, Meischl C, Heitbrink MA, Schreurs WH. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation. Dis Colon Rectum. 2017;60(3):274–83.
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer. 2017;117(10):1478–85.
Coskun M, Mehralivand S, Shih JH, Merino MJ, Wood BJ, Pinto PA, Barrett T, Choyke PL, Turkbey B. Impact of bowel preparation with Fleet’s™ enema on prostate MRI quality. Abdom Radiol. 2020;45(12):4252–9.
Ogura A, Konishi T, Beets GL, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, Lee IK, Lee HX, Uehara K, et al. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg. 2019;154(9):e192172.
Fujita S, Yamamoto S, Akasu T, Moriya Y. Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Colorectal Dis. 2009;24(9):1085–90.
Acknowledgements
This work was supported by Department of Science and Technology of Sichuan Province (No. 2021YFS0025), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. 20HXJS003), 1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, and West China Hospital, Sichuan University (No. 22HXFH001 and 2019HXFH031).
Author information
Authors and Affiliations
Contributions
XL and XY: statistical analysis, data interpretation, submission, clinical interpretation, editing, and writing; QW: statistical analysis, data interpretation, editing; TZ: image data provider; DJ: pathological data provider; ZW: principal investigator, conceptualization, operative performer. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This single-center cohort study was ethically approved by West china hospital Medical Ethics Committee and exempted from informed consent. Our research strictly abides by the Declaration of Helsinki and the International Ethical Guidelines for Biomedical Research Involving Human Subjects.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Table S1.
Evaluation criteria of MRF. Table S2. Evaluation criteria of EMVI. Table S3. Evaluation criteria of MRI-positive LLN before and after nCRT. Figure S1. The method for determining the correspondence between the LLN and the pathological outcomes. The scissors point to the LLN with the maximum short-axis.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, X., Yang, X., Wu, Q. et al. Can patients with good tumor regression grading after neoadjuvant chemoradiotherapy be exempted from lateral lymph node dissection?. Discov Onc 13, 144 (2022). https://doi.org/10.1007/s12672-022-00607-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12672-022-00607-w